Abstract：
Capecitabine, a prodrug of 5-fluorouracil, is an FDA-approved drug for adjuvant treatment of colon, metastatic colorectal, and breast cancer. A variety of mucocutaneous adverse effects has been recognized with capecitabine. The pathogenesis of such manifestations still remains an enigma though various theories have been proposed. Here, we report two such cases. A 59-year-old female with carcinoma of the sigmoid colon on palliative therapy developed localized cutaneous hyperpigmentation of the palms and soles secondary to capecitabine in her 2nd cycle. Another case was of a 42-year-old female with stomach adenocarcinoma, who developed similar adverse effects after administration of capecitabine in her 4th cycle. Since these drugs have been widely used in recent years due to their relative ease in administration, the relative unawareness of Hand-foot syndrome (HFS) caused due to this drug makes it a prudent topic to be reported.
摘要：
卡培他滨,5-氟尿嘧啶的前药，是FDA批准的结肠辅助治疗药物，转移性结直肠，和乳腺癌。卡培他滨已认识到多种皮肤粘膜副作用。尽管已经提出了各种理论，但此类表现的发病机理仍然是一个谜。这里,我们报告了两起这样的案件。一名59岁的女性在姑息治疗中患有乙状结肠癌，在第二个周期中继发于卡培他滨，出现了手掌和脚底的局部皮肤色素沉着。另一例是一名42岁女性胃腺癌，她在第4个周期服用卡培他滨后出现了类似的不良反应。由于这些药物由于其给药相对容易，近年来已被广泛使用，由于这种药物引起的手足综合征（HFS）的相对认识不足，因此值得报道。
